McCaffrey Anton P, Nakai Hiroyuki, Pandey Kusum, Huang Zan, Salazar Felix H, Xu Hui, Wieland Stefan F, Marion Patricia L, Kay Mark A
Department of Pediatrics, Stanford University School of Medicine, 300 Pasteur Drive, Room G305, Stanford, California, USA.
Nat Biotechnol. 2003 Jun;21(6):639-44. doi: 10.1038/nbt824. Epub 2003 May 12.
Hepatitis B virus (HBV) infection substantially increases the risk of chronic liver disease and hepatocellular carcinoma in humans. RNA interference (RNAi) of virus-specific genes has emerged as a potential antiviral mechanism. Here we show that RNAi can be applied to inhibit production of HBV replicative intermediates in cell culture and in immunocompetent and immunodeficient mice transfected with an HBV plasmid. Cotransfection with plasmids expressing short hairpin RNAs (shRNAs) homologous to HBV mRNAs induced an RNAi response. Northern and Southern analyses of mouse liver RNA and DNA showed substantially reduced levels of HBV RNAs and replicated HBV genomes upon RNAi treatment. Secreted HBV surface antigen (HBsAg) was reduced by 94.2% in cell culture and 84.5% in mouse serum, whereas immunohistochemical detection of HBV core antigen (HBcAg) revealed >99% reduction in stained hepatocytes upon RNAi treatment. Thus, RNAi effectively inhibited replication initiation in cultured cells and mammalian liver, showing that such an approach could be useful in the treatment of viral diseases.
乙型肝炎病毒(HBV)感染显著增加了人类患慢性肝病和肝细胞癌的风险。病毒特异性基因的RNA干扰(RNAi)已成为一种潜在的抗病毒机制。在此,我们表明RNAi可用于抑制细胞培养以及用HBV质粒转染的免疫健全和免疫缺陷小鼠中HBV复制中间体的产生。与表达与HBV mRNA同源的短发夹RNA(shRNA)的质粒共转染可诱导RNAi反应。对小鼠肝脏RNA和DNA的Northern和Southern分析表明,RNAi处理后HBV RNA和复制的HBV基因组水平大幅降低。在细胞培养中,分泌的HBV表面抗原(HBsAg)减少了94.2%,在小鼠血清中减少了84.5%,而RNAi处理后,对HBV核心抗原(HBcAg)的免疫组织化学检测显示,染色的肝细胞减少了>99%。因此,RNAi有效抑制了培养细胞和哺乳动物肝脏中的复制起始,表明这种方法可能对治疗病毒性疾病有用。